Clinical Trials in Colorado

Showing 6401-6420 of 13,761 trials

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

NCT00981162

This phase I/II trial is studying the side effects and best dose of everolimus when given together with sorafenib tosylate and to see how well they work in treating patients with advanced solid tumors and metastatic pancreatic cancer that does not respond to gemcitabine hydrochloride. Sorafenib tosylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Giving sorafenib tosylate together with everolimus may kill more tumor cells.

Acinar Cell Adenocarcinoma of the PancreasDuct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic Cancer+2 more

Roswell Park Cancer Institute12 participantsStarted Aug 2009

Aurora, Colorado, United States • Buffalo, New York, United States

COMPLETEDPhase 153 miles

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

NCT01920061

This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors. The study will assess the safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer in order to determine the maximum tolerated dose in each combination. The cisplatin combination expansion portion will evaluate the anti tumor activity of PF 05212384 plus cisplatin in patients with TNBC in 2 separate Arms (Arm 1 and Arm 2).

Neoplasm

Pfizer110 participantsStarted Sep 2013

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Los Angeles, California, United States +26 more locations

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Find Trials by Condition in Colorado

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection

Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

Evaluation of the Use of Medical Scribes in VAMC Emergency Departments and Specialty Care Clinics

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia

Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)

MR-Guided Focused Ultrasound in the Treatment of Focal Epilepsy (EP001)

A Prospective Study of Early Mechanical Stabilization and Bleeding in Disruption of the Pelvic Ring

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma